CDT Equity Inc. (NASDAQ:CDT) Short Interest Update

CDT Equity Inc. (NASDAQ:CDT) was the target of a significant growth in short interest in February. As of February 27th, there was short interest totaling 177,766 shares, a growth of 140.0% from the February 12th total of 74,063 shares. Approximately 8.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,449,064 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily trading volume, of 1,449,064 shares, the days-to-cover ratio is presently 0.1 days. Approximately 8.4% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CDT Equity in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On CDT Equity

An institutional investor recently bought a new position in CDT Equity stock. Apollon Wealth Management LLC bought a new stake in CDT Equity Inc. (NASDAQ:CDT) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 107,454 shares of the company’s stock, valued at approximately $73,000. Apollon Wealth Management LLC owned approximately 28.28% of CDT Equity as of its most recent SEC filing. 3.29% of the stock is owned by hedge funds and other institutional investors.

CDT Equity Trading Down 18.9%

Shares of NASDAQ CDT opened at $0.48 on Friday. The stock has a market cap of $1.10 million, a PE ratio of 0.00 and a beta of 1.84. CDT Equity has a 12-month low of $0.47 and a 12-month high of $168.00. The company has a 50-day moving average of $1.06 and a 200 day moving average of $2.92.

About CDT Equity

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.